A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
In brief
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Key facts
- Study ID
- NCT07116889
- Run by
- Generate Biomedicines
- People needed
- 156
- Starts
- 2023-12-12
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2025-11-05
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alcanza — DeLand, Florida, United States
- Miami Research Institute of South Florida — Miami, Florida, United States
- Omega Research — Orlando, Florida, United States
- Nucleus Network — Saint Paul, Minnesota, United States
- Southeastern Research Center — Winston-Salem, North Carolina, United States
- DM Clinical Research — Tomball, Texas, United States
- Charite Research Organization GmbH — Berlin, Germany
- IKF Pneumologie — Frankfurt, Germany
- Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM) — Hanover, Germany
- Hammersmith Medicines Research — London, United Kingdom
- Queen Anne Street Medical Center — London, United Kingdom
- Medicines Evaluation Unit (MEU) — Manchester, United Kingdom
- Simbec-Orion Clinical Development — Merthyr Tydfil, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.